Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Eric Läwitz"'
Autor:
Philip N. Newsome, Arun J. Sanyal, Guy Neff, Jörn M. Schattenberg, Vlad Ratziu, Judith Ertle, Jasmin Link, Alison Mackie, Corinna Schoelch, Eric Lawitz, BI 1467335 NASH Phase IIa trial team
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-11 (2023)
Abstract Non-alcoholic steatohepatitis (NASH) is a progressive, inflammatory liver disease with no approved pharmacological treatment. This Phase IIa, double-blind, placebo-controlled, multicentre trial (ClinicalTrials.gov: NCT03166735) investigated
Externí odkaz:
https://doaj.org/article/f8f75d8f1dd9428aae4a8f04531f0a04
Autor:
Eric Lawitz, Edward Gane, Eric Cohen, John Vierling, Kosh Agarwal, Tarek Hassanein, Parvez S. Mantry, Paul J. Pockros, Michael Bennett, Nyingi Kemmer, Giuseppe Morelli, Jiuhong Zha, Deli Wang, Nancy S. Shulman, Daniel E. Cohen, K. Rajender Reddy
Publikováno v:
Kidney International Reports, Vol 4, Iss 2, Pp 257-266 (2019)
Introduction: Hepatitis C virus (HCV) infection is common in patients with end-stage renal disease. We investigated the safety and efficacy of ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) ± dasabuvir (DSV) ± ribavirin (RBV) in 2 phase 3, open-
Externí odkaz:
https://doaj.org/article/4057d33cf90442e09159e38451382b6a
Autor:
Fabien Zoulim, Christophe Moreno, Samuel S. Lee, Peter Buggisch, Andrzej Horban, Eric Lawitz, Chris Corbett, Oliver Lenz, Bart Fevery, Thierry Verbinnen, Umesh Shukla, Wolfgang Jessner
Publikováno v:
Virology Journal, Vol 15, Iss 1, Pp 1-11 (2018)
Abstract Background Simeprevir is approved with pegylated interferon and ribavirin (PR) for chronic hepatitis C virus (HCV) genotype (GT) 1 and GT4 infection in the USA and the European Union. Methods This 3-year follow-up study assessed the durabili
Externí odkaz:
https://doaj.org/article/12546fb5318c449181ab2d29342193b1
Autor:
Naim Alkhouri, Casey Johnson, Leon Adams, Sachiko Kitajima, Chikayuki Tsuruno, Tracey L Colpitts, Kazuki Hatcho, Eric Lawitz, Rocio Lopez, Ariel E Feldstein
Publikováno v:
PLoS ONE, Vol 13, Iss 8, p e0202226 (2018)
OBJECTIVE:The race for finding effective treatments for nonalcoholic fatty liver disease (NAFLD) has been slowed down by the high screen-failure rate for including patients in trials due to the lack of a noninvasive biomarker that can identify patien
Externí odkaz:
https://doaj.org/article/20a13ae501ec4a1c9495fb50653061b8
Autor:
Naim Alkhouri, Casey Johnson, Leon Adams, Sachiko Kitajima, Chikayuki Tsuruno, Tracey L Colpitts, Kazuki Hatcho, Eric Lawitz, Rocio Lopez, Ariel E Feldstein
Publikováno v:
PLoS ONE, Vol 13, Iss 10, p e0205541 (2018)
[This corrects the article DOI: 10.1371/journal.pone.0202226.].
Externí odkaz:
https://doaj.org/article/24e566443b294aebb906deeb6a0eedfe
Autor:
David Gardiner, Jay Lalezari, Eric Lawitz, Michael DiMicco, Rheem Ghalib, K Rajender Reddy, Kyong-Mi Chang, Mark Sulkowski, Steven O' Marro, Jeffrey Anderson, Bing He, Vikram Kansra, Fiona McPhee, Megan Wind-Rotolo, Dennis Grasela, Mark Selby, Alan J Korman, Israel Lowy
Publikováno v:
PLoS ONE, Vol 8, Iss 5, p e63818 (2013)
Expression of the programmed death 1 (PD-1) receptor and its ligands are implicated in the T cell exhaustion phenotype which contributes to the persistence of several chronic viral infections, including human hepatitis C virus (HCV). The antiviral po
Externí odkaz:
https://doaj.org/article/5889a97179954738bd4d816026b9389b
Autor:
Maribel Rodriguez-Torres, Eric Läwitz, Bienvenido Yangco, Lennox Jeffers, Steven-Huy Han, Paul J. Thuluvath, Vinod Rustgi, Stephen Harrison, Reem Ghalib, John M. Vierling, Velimir Luketic, Philippe J. Zamor, Natarajan Ravendhran, Timothy R. Morgan, Brian Pearlman, Christopher O’Brien, Hicham Khallafi, Nikolaos Pyrsopoulos, George Kong, Fiona McPhee, Philip D. Yin, Eric Hughes, Michelle Treitel
Publikováno v:
Annals of Hepatology, Vol 15, Iss 6, Pp 834-845 (2016)
Background. Patient race and ethnicity have historically impacted HCV treatment response. This phase 3 study evaluated daclatasvir with peginterferon-alfa-2a/ribavirin (pegIFN alfa-2a/RBV) in treatment-naive black/African American (AA), Latino, and w
Externí odkaz:
https://doaj.org/article/758320977acf45fe990b1d476981cdbb
Autor:
Steven Flamm, Eric Lawitz, Brian Borg, Michael Charlton, Charles Landis, K. Rajender Reddy, Mitchell Shiffman, Angel Alsina, Charissa Chang, Natarajan Ravendhran, Candido Hernandez, Christophe Hézode, Stacey Scherbakovsky, Renee-Claude Mercier, Didier Samuel
Publikováno v:
Viruses, Vol 15, Iss 10, p 2026 (2023)
A fixed-dose combination of sofosbuvir/velpatasvir (SOF/VEL) plus weight-based ribavirin (RBV) for 12 weeks is recommended for the treatment of patients with hepatitis C virus (HCV)-associated decompensated cirrhosis. However, large global studies, w
Externí odkaz:
https://doaj.org/article/620ad64d8bc644198848a98512cd84c1
Autor:
Eric Lawitz, Fred Poordad, Julio A. Gutierrez, Maria Beumont, Greet Beets, Ann Vandevoorde, Pieter Van Remoortere, Donghan Luo, Leen Vijgen, Veerle Van Eygen, Mohamed Gamil
Publikováno v:
Health Science Reports, Vol 3, Iss 2, Pp n/a-n/a (2020)
Abstract Background and aims Direct‐acting antiviral agents (DAAs) for hepatitis C virus (HCV) infection have resulted in high rates of sustained virologic response (SVR) following 8 to 24 weeks of treatment. However, difficult‐to‐cure/cirrhoti
Externí odkaz:
https://doaj.org/article/61e6a0119abd4699b62cba409899ce21
Publikováno v:
Hepatology Communications, Vol 2, Iss 7, Pp 778-785 (2018)
Nonalcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of insulin resistance, which is the hallmark of type 2 diabetes (T2D). NAFLD is a known risk factor for developing T2D and has a very high prevalence in those with exist
Externí odkaz:
https://doaj.org/article/d4611e839e434658bf0848f4128246b0